Evidence map›Paper›PMID 42013843›Full record

ArticleCell reports. Medicine2026

Debio 1562M CD37-targeting ADC is highly active and well tolerated in preclinical models of AML and MDS.

Léo Marx, Josée Hue-Perron, Alain Monjardet, Selena Vigano, Christophe Chardonnens, Kaitlin Morse, Esthela Artiga, Marie-Claude Roubaudi-Fraschini, René Wuttke, Riccardo Colombo and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Léo MarxDebiopharm Research and Manufacturing SA, 1920 Martigny, Switzerland.
Josée Hue-PerronDebiopharm International SA, 1006 Lausanne, Switzerland.
Alain MonjardetDebiopharm International SA, 1006 Lausanne, Switzerland.
Selena ViganoDebiopharm Research and Manufacturing SA, 1920 Martigny, Switzerland.
Christophe ChardonnensDebiopharm Research and Manufacturing SA, 1920 Martigny, Switzerland.
Kaitlin MorseComprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Esthela ArtigaComprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Marie-Claude Roubaudi-FraschiniDebiopharm International SA, 1006 Lausanne, Switzerland.
René WuttkeDebiopharm International SA, 1006 Lausanne, Switzerland.
Riccardo ColomboDebiopharm International SA, 1006 Lausanne, Switzerland.
Karilyn LarkinComprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
Lisa IvanschitzDebiopharm International SA, 1006 Lausanne, Switzerland. Electronic address: lisa.ivanschitz@debiopharm.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The leukocyte antigen CD37 is broadly expressed on acute myeloid leukemia (AML) blasts and associated with poor prognosis. We demonstrate that myelodysplastic syndrome (MDS) cells also express CD37, and both AML and MDS cells have favorable internalization properties of this receptor. Debio 1562M is a next-generation antibody-drug conjugate (ADC) that targets CD37 and is optimized to deliver more toxins to tumor cells than the first-generation ADC Debio 1562, while maintaining a good safety profile. Preclinically, Debio 1562M showed robust anti-leukemic activity in AML and MDS primary samples and in AML xenograft models, irrespective of disease stage or genotype. Debio 1562M was able to target leukemic stem cells in vitro and significantly decrease tumor burden in blood and bone marrow, resulting in survival prolongation compared with standard-of-care treatments. These data demonstrate that CD37 is a relevant target for both indications and that Debio 1562M is a promising therapeutic candidate.

Indexed as

Antigens, NeoplasmImmunoconjugatesLeukemia, Myeloid, AcuteMyelodysplastic SyndromesTetraspaninsAnimalsCell Line, TumorFemaleHumansMaleMiceMice, SCIDXenograft Model Antitumor AssaysAntigens, NeoplasmCD37 protein, humanImmunoconjugatesTetraspaninsacute myeloid leukemiaantibody-drug conjugateCD37cleavable linkerDebio 1562MMultilink linker technologymyelodysplastic syndromepatient-derived xenograftspreclinical assessment

Identifiers

PMID42013843
PMCPMC13198232

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.